Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California. Show more
Location: 2200 Bridge Pkwy, Redwood City, CA, 94065, United States | Website: https://jaspertx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
38.68M
52 Wk Range
$2.27 - $26.05
Previous Close
$2.38
Open
$2.38
Volume
116,635
Day Range
$2.36 - $2.50
Enterprise Value
2.141M
Cash
39.51M
Avg Qtr Burn
-18.37M
Insider Ownership
1.17%
Institutional Own.
78.28%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Briquilimab (SC) Details Chronic spontaneous urticaria (CSU) | Phase 1/2 Data readout | |
Briquilimab (SC) Details Cold urticaria (ColdU) or symptomatic dermographism (SD) | Phase 1/2 Update | |
Briquilimab Details Severe combined immunodeficiency due to complete RAG1/2 deficiency | Failed Discontinued | |
Briquilimab (SA SC) Details Asthma | Failed Discontinued |